Emmaus Life SciencesEMMA +14.37% 3-Year RORE % is 13.79 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 1,294 Biotechnology companies, Emmaus Life Sciences ranks better than 76.97% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Emmaus Life Sciences's 3-Year RORE % for the quarter that ended in Mar. 2026 was 13.79%.
The industry rank for Emmaus Life Sciences's 3-Year RORE % or its related term are showing as below:
EMMA's 3-Year RORE % is ranked better than 76.97% of 1294
companies
in the Biotechnology industry
Industry Median: -11.54
vs EMMA: 13.79
Emmaus Life Sciences (OTCPK:EMMA) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Emmaus Life Sciences 3-Year RORE % Related Terms
Emmaus Life Sciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs PTIX, BZYR, RMTG: 3-Year RORE % Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Emmaus Life Sciences (EMMA) has a 3-Year RORE % of 13.79 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #298 out of 1294 companies in the Biotechnology industry, placing it in the top 23%.
Is Emmaus Life Sciences' 3-Year RORE % too high?
Emmaus Life Sciences' current 3-Year RORE % is 13.79. Based on the distribution chart, Emmaus Life Sciences ranks #298 out of 1294 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' 3-Year RORE % compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #298 out of 1294 companies for 3-Year RORE %. This places Emmaus Life Sciences in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current 3-Year RORE % is 13.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 17% above its estimated fair value. The current 3-Year RORE % is 13.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current 3-Year RORE % is 13.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 